A preliminary study of diabetic vascular diseases induced by advanced glycosylation end products

刘言言,黄楷,郎江莉,杨川
DOI: https://doi.org/10.3760/cma.j.cn101411-20200319-00028
2020-01-01
Abstract:Objective:To investigate the role of advanced glycosylation end products (AGEs) in proliferation and apoptosis of human umbilical vein endothelial (HUVEC) cells, and to preliminarily explore the potential mechanism of microrna-375 (miR-375) and YAP (Yes-associated protein) in diabetic vascular diseases.Methods:HUVECs were incubated with BSA or AGEs (0, 50, 100, 200 μg/ml) for different periods(24, 28,72 h), cell- counting kit (CCK8) and Edu assay were utilized to detect cell viability and proliferation. Apoptosis was characterized by flow cytometry with FITC annexin-v and piridine iodide (PI) staining. The miR-375 and YAP levels in BSA and AGEs groups were measured by RT-qPCR and Western Blot.Results:AGEs did not affect HUVECs [200 μg/ml BSA (0.1500±0040) vs AGEs(0.1560±0.0085), P=0.064] in the first 24h but inhibited the cell viability [200 μg/ml BSA (0.2516±0.0143) vs AGEs(0.2150±0.010), P=0.033] after 48h according to the CCK8 results. After being stimulated with 200 μg/ml AGEs, the proliferation of HUVECs were decreased with Edu assay [200 μg/ml BSA (17.1025±0.4597)% vs AGEs (10.9387±0.6680)%, P=0.025] but apoptosis did not increase according to Flow cytometry results [200 μg/ml BSA (8.1667±0.3055)% vs AGEs (8.2167±0.5507)%, P=0.609]. RT-qPCR and Western Blot reveal that the expression of miR-375 ( P=0.032) and YAP were significantly higher in AGEs group ( P=0.039) . Conclusion:AGEs inhibited the proliferation of HUVECs and promoted miR-375 and YAP expression in HUVECs. However, theunderlying molecular mechanisms need further study.
What problem does this paper attempt to address?